Speed of improvement in cancer survival rates ‘slowing', say experts
The news comes as a study suggests survival between the most and least deadly types of the disease is wider than ever before.
A national cancer plan was 'essential' to 'bring cancer survival trends back towards the best in the world', researchers said.
The study, led by the London School of Hygiene and Tropical Medicine (LSHTM) and funded by Cancer Research UK, analysed long-term trends in the cancer survival index (CSI) for adults across England and Wales from 1971 to 2018.
Using records from the National Disease Registration Service for England and the Welsh Cancer Intelligence and Surveillance Unit, experts estimated net survival for up to 10 years after diagnosis for around 10.8 million people.
They found that in 2018, the CSI for all cancers combined a decade after diagnosis was 49.8%, higher than the CSI at one year for those diagnosed in 1971/72.
Researchers hailed the figure as 'remarkable', but warned that the 'speed of improvement in survival has slowed down'.
In the five years from 2000/01 to 2005/06, the 10-year CSI rose by 4%, from 41.2% to 45.2%.
But between 2010/11 and 2015/16, the rise was 1.4%, from 47.9% to 49.3%.
There were also major gaps in survival when it came to different cancer types.
For example, 10-year survival for testicular cancer was 97%, compared with 4.3% for pancreatic cancer.
Screening programmes had bolstered survival rates for cancers in the breast, bowel and cervix, according to Cancer Research UK.
But survival for other types, such as stomach, lung and brain cancer, had increased by only a small amount in the past 50 years.
Writing in the Lancet Regional Health – Europe, researchers warned this slowdown for individual cancers implied a 'system-wide challenge'.
Michelle Mitchell, chief executive of Cancer Research UK, said: 'Thanks to research, most patients today are far more likely to survive their cancer than at any point in the past.
'But the reality is that this progress is slowing – and for some cancers, it never got going in the first place.'
The Government launched a call for evidence to help shape a national cancer plan in February.
The blueprint aims to outline actions to transform how the disease is treated in a bid to reduce deaths.
Ms Mitchell said: 'The upcoming National Cancer Plan for England must include commitments to spot more cancers earlier, as well as backing research into new treatments so that each patient, regardless of their diagnosis, can hope for more moments with the people they love.'
Michel Coleman, a professor of epidemiology and statistics at LSHTM, said: 'Since I began my career in cancer research, I've seen substantial increases in survival for most types of cancer.
'Our understanding of cancer biology has expanded, effective screening programmes have been introduced, and new treatments have been developed. Allowing this trend to stall will have devastating consequences.
'This study was only possible because of data on millions of patients from cancer registries in England and Wales.
'It's vital that the Government provides the political and financial support to ensure we maintain this crucial data. Without these, the Government will be flying blind on cancer control.
'The National Cancer Plan is a chance to improve NHS cancer pathways and reap the benefits of new research – the Government must take it.'
Cancer Research UK is calling for the national cancer plan to slash waiting times for diagnosis and treatment, saying some patients face unacceptable delays.
The plan should also improve early diagnosis of cancer, with plans to boost participation in existing screening programmes and a commitment to rolling out lung cancer screening fully in England by 2029.
A Department of Health and Social Care spokesperson said: 'We are prioritising cancer care as we turn around more than a decade of neglect of our NHS.
'We're already seeing progress, with 95,000 more people having cancer diagnosed or ruled out within 28 days between July 2024 and May 2025, compared to the same period the previous year.
'The National Cancer Plan will set out how we will improve survival rates further and address the variation between different cancer types.'
Get all the latest news from around the country Follow STV News
Scan the QR code on your mobile device for all the latest news from around the country
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Times
an hour ago
- Times
‘Functional beverages' are booming — but is it all hype?
Before you take that magnesium supplement or sit down to meditate, what if a drink could help you relax? Enter 'functional beverages', drinks that claim to possess additional health benefits beyond those of a standard fizzy drink or fruit juice. Functional drinks are surging in popularity, with supermarkets in Britain seeing sales increase by 24.5 per cent in the past year, according to Worldpanel by Numerator. The market research firm also said that almost 30 per cent of UK households now purchase functional drinks. However, Nichola Ludlam-Raine, a dietician with more than 15 years of clinical experience in the NHS, has warned that she 'wouldn't rely on them [functional drinks] for measurable health benefits'. Ludlam-Raine, who now works privately and is the author of How Not to Eat Ultra-Processed , said: 'Functional drinks containing ingredients like CBD [cannabidiol], lion's mane [a type of mushroom], and ashwagandha [a herb typically used in ayurvedic medicine] are part of a growing wellness trend, but the science isn't as strong as the marketing.'
The Guardian
2 hours ago
- The Guardian
The Guardian view on regulating cosmetic procedures: rogue operators must be tackled, but aren't the only problem
The enormous popularity of beauty treatments, including dermatological fillers and Botox injections, is not solely an issue for health regulators. Changing norms and aspirations about appearances, and the way that these are marketed mainly to women and girls, are a cultural and economic phenomenon that requires wider consideration. While attitudes to these procedures and aesthetics vary, many people – including some cosmetic surgeons – are concerned that younger women account for a growing share of a highly lucrative and growing market. The death last year of 33-year-old Alice Webb in Gloucestershire, after a non-surgical Brazilian butt lift, as well as multiple reports of injuries, and the deaths of at least 28 women who have travelled to Turkey for cosmetic treatments, have increased the pressure on ministers to tighten the law. Wes Streeting's announcement of new licence requirements for UK businesses, and tighter regulation of higher-risk treatments, is probably overdue. The Chartered Trading Standards Institute recently warned that untrained people have given cosmetic injections in public toilets and hotels. Altering the law in order to exclude such 'rogue operators' ought to make high streets and the internet – where many clinics advertise – safer. Talking about the risks, as the health secretary has been doing, and holding a consultation on proposed changes, may have the beneficial effect of raising awareness even before changes are introduced. But councils will need resources if they are to be expected to enforce new rules by issuing licences, checking premises and so on. As in many other areas of economic activity, the law on its own is unlikely to be enough. Mechanisms are needed to ensure that businesses comply. It is already illegal to administer Botox or dermal fillers to children in England – although, worryingly, it is still allowed in Wales and Scotland. Mr Streeting's announcement that rules regarding children will be tightened further is particularly welcome. Strenuous efforts should be made to place them off limits for the industry as a whole. The reported preoccupation of some children with anti-ageing products is not healthy and should be discouraged. Mr Streeting did not refer to the cost to the NHS if cosmetic procedures go wrong, when announcing plans to tighten the law. But Karin Smyth, one of his ministers, has raised this. And Prof Sir Stephen Powis, who was NHS England's national medical director until last month, made the same point specifically in relation to butt lifts – the cosmetic procedure with the highest death rate of all. Ministers should expect pushback even though many experts, including plastic surgeons, favour tighter rules. The pro-growth mood of the Treasury means proposals for new regulations are unlikely to be smiled upon there. The more restrictive approach being proposed for England will also do nothing to prevent surgical tourism and could even increase it, if tighter regulation of the domestic industry results in higher prices. The gap in safeguards that allows foreign cosmetic surgery providers to market directly to the public needs to be addressed separately, which the government has begun to recognise. There is no single or instant fix. But by cracking down on cowboy operators, ministers will send a message that appearance-altering injections and other invasive treatments must be treated seriously. They are a different order of activity from applying makeup or painting nails. Do you have an opinion on the issues raised in this article? If you would like to submit a response of up to 300 words by email to be considered for publication in our letters section, please click here.
Times
3 hours ago
- Times
Obese to get soups and shakes diet instead of weight-loss jabs
Low-calorie soups and shakes are to be prescribed to thousands of overweight people in Scotland in an attempt to reduce their dependence on expensive weight-loss drugs and provide longer-lasting health benefits. From January, 3,000 patients who have been newly diagnosed with type 2 diabetes will be recruited for a clinical trial. About 300,000 Scots live with type 2 diabetes, a condition commonly linked to obesity, in which badly regulated blood sugar levels can increase the risk of heart disease, kidney disease, strokes or nerve conditions. About 10,000 of them are being treated with weight-loss drugs such as Ozempic, Wegovy and Mounjaro, with injections costing the NHS £3,000 a year. The estimated annual bill of £30 million is expected to rise as manufacturers raise prices. NHS chiefs believe that not only will the soups and shakes plan be less expensive, it will also bring longer-term health benefits. In the Total Diet Replacement (TDR) plan, to be rolled out over three years, patients who have recently been diagnosed with type 2 diabetes and are deemed eligible will be given low-calorie substitutes for their breakfast, lunch and dinner. The replacement meals, containing a maximum of 900 calories a day, will be delivered to patients for between three and five months. • What to do now Mounjaro's hiking its prices, by an obesity expert After this initial period, normal food will be reintroduced, but with guidance given on healthy meals through online consultations and an app. The ambition is for patients to lose up to 10 per cent of their body weight over a year. Doctors are also optimistic that up to 40 per cent of the trial participants will achieve remission from type 2 diabetes within a year. There are fears that the weight lost through injections — which work by suppressing the appetite — may last only as long as the patient is taking the drug. By contrast, the effects of diet changes should prove more long-lasting and cost effective, NHS officials believe. The TDR scheme is set to cost £5.6 million for 3,000 patients, a one-off cost of about £1,866 per person. Doctors hope the plan will help patients to fundamentally alter their diet and lifestyle. A spokesman for the Scottish government said: 'We anticipate that around 35 to 40 per cent will achieve remission from type 2 diabetes at the end of their first year on the programme, with a majority of patients benefiting from a clinically significant average weight loss of 10 per cent.' This would lead to reductions in blood pressure and contribute to a reduced risk of cardiovascular disease. He added: 'We will measure impact by the number of patients recruited into this programme, the number who achieve remission and the number with clinically significant weight loss.'
